The FDA’s Oncologic Drugs Advisory Committee voted in favor of approving tazemetostat tablets as a treatment for patients with metastatic or locally advanced epithelioid sarcoma that is ineligible for curative surgery.
Adjuvant anlotinib was safe and led to a DFS benefit vs surgery alone in completely resected high-grade soft tissue sarcoma.
Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.
Initial fruquintinib followed by regorafenib extended OS vs the reverse sequence of the agents in patients with metastatic colorectal cancer.
Padeliporfin vascular targeted photodynamic therapy was safe and generated responses in low-grade, upper tract urothelial cancer.
FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.
Fruquintinib plus capecitabine demonstrated preliminary efficacy and safety as maintenance therapy in RAS/BRAF wild-type metastatic colorectal cancer.
The EMA’s CHMP has recommended the approval for acalabrutinib/venetoclax with or without obinutuzumab in untreated CLL.
The FDA approved a ready-to-dilute formulation of thiotepa in a multi-dose vial for the treatment with breast and ovarian cancer.
Breast cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
No recurrences, disease-free survival events, or deaths were reported in select patients with breast cancer who had surgery omitted.
